Retraction: p53 Modulates Hsp90 ATPase Activity and Regulates Aryl Hydrocarbon Receptor Signaling (Cancer Prev Res (2014) 7 (596–606) DOI: 10.1158/1940-6207.CAPR-14-0051);p53 modulates Hsp90 ATPase activity and regulates aryl hydrocarbon receptor signaling

Cancer Prevention Research

Volumn 7, Issue 6, 2014, Pages 596-606

  Kochhar, Amit ^a,d   Kopelovich, Levy ^a   Sue, Erika ^a   Guttenplan, Joseph B ^b,c   Herbert, Brittney Shea ^e   Dannenberg, Andrew J ^a   Subbaramaiah, Kotha ^a  

^a NEW YORK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ADENOSINE TRIPHOSPHATASE; AROMATIC HYDROCARBON RECEPTOR; BENZO[A]PYRENE; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; HEAT SHOCK PROTEIN 90; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P53; CYP1A1 PROTEIN, HUMAN; CYP1B1 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FAMILIAL CANCER; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; METABOLISM; MODULATION; MUTANT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL CULTURE; CELL TRANSFORMATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; PHYSIOLOGY; PROTEIN TRANSPORT;

ADENOSINE TRIPHOSPHATASES; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1B1; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; POLYCYCLIC HYDROCARBONS, AROMATIC; PROTEIN TRANSPORT; RECEPTORS, ARYL HYDROCARBON; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903553389     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-22-0207     Document Type: Erratum

References (50)

1. Kasai A, Hiramatsu N, Hayakawa K, Yao J, Maeda S, Kitamura M. High levels of dioxin-like potential in cigarette smoke evidenced by in vitro and in vivo biosensing. Cancer Res 2006;66:7143-50. (Pubitemid 44197692)
2. Shimizu Y, Nakatsuru Y, Ichinose M, Takahashi Y, Kume H, Mimura J, et al. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A 2000;97:779-82. (Pubitemid 30070386)
3. Moennikes O, Loeppen S, Buchmann A, Andersson P, Ittrich C, Poellinger L, et al. A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res 2004;64:4707-10. (Pubitemid 38924510)
4. Boyle JO, Gumus ZH, Kacker A, Choksi VL, Bocker JM, Zhou XK, et al. Effects of cigarette smoke on the human oral mucosal transcriptome. Cancer Prev Res 2010;3:266-78.
5. Port JL, Yamaguchi K, Du B, De Lorenzo M, Chang M, Heerdt PM, et al. Tobacco smoke induces CYP1B1 in the aerodigestive tract. Carcinogenesis 2004;25:2275-81. (Pubitemid 39534867)
6. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, et al. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 1990;82:1333-9. (Pubitemid 20238488)
7. Harrigan JA, Vezina CM, McGarrigle BP, Ersing N, Box HC, Maccubbin AE, et al.DNAadduct formation in precision-cut rat liver and lung slices exposed to benzo[a]pyrene. Toxicol Sci 2004;77:307-14. (Pubitemid 38262604)
8. Volk DE, Thiviyanathan V, Rice JS, Luxon BA, Shah JH, Yagi H, et al. Solution structure of a cis-opened (10R)-N6-deoxyadenosine adduct of (9S,10R)-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene in a DNA duplex. Biochemistry 2003;42:1410-20. (Pubitemid 36205947)
9. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-2. (Pubitemid 26353359)
10. Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 2000;92:803-11. (Pubitemid 30368036)
11. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013;15:2-8.
12. Gaglia G, Guan Y, Shah JV, Lahav G. Activation and control of p53 tetramerization in individual living cells. Proc Natl Acad Sci U S A 2013;110:15497-501.
13. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137:413-31.
14. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
15. Soussi T, Ishioka C, Claustres M, Beroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer 2006;6:83-90. (Pubitemid 43053654)
16. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53:4477-80. (Pubitemid 23304366)
17. Lazarus P, Garewal HS, Sciubba J, Zwiebel N, Calcagnotto A, Fair A, et al. A low incidence of p53 mutations in pre-malignant lesions of the oral cavity from non-tobacco users. Int J Cancer 1995;60:458- 63.
18. Qin GZ, Park JY, Chen SY, Lazarus P. A high prevalence of p53 mutations in pre-malignant oral erythroplakia. Int J Cancer 1999;80:345-8. (Pubitemid 29019618)
19. Okayama S, Kopelovich L, Balmus G, Weiss RS, Herbert BS, Dannenberg AJ, et al. p53 regulates Hsp90 ATPase activity and thereby Wnt signaling by modulating Aha1 expression. J Biol Chem 2014;289:6513-25.
20. Rao CV, Swamy MV, Patlolla JM, Kopelovich L. Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+mice. Cancer Res 2008;68:7670-5.
21. Athar M, Elmets CA, Kopelovich L. Pharmacological activation of p53 in cancer cells. Curr Pharm Des 2011;17:631-9.
22. Sacks PG. Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck. Cancer Metastasis Rev 1996;15:27-51. (Pubitemid 26248350)
23. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A 1992;89:4495-9.
24. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000;14:981-93. (Pubitemid 30253006)
25. Shay JW, Tomlinson G, Piatyszek MA, Gollahon LS. Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome. Mol Cell Biol 1995;15:425-32. (Pubitemid 24379941)
26. Herbert BS, Chanoux RA, Liu Y, Baenziger PH, Goswami CP, McClintick JN, et al. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. Oncotarget 2010;1:405-22.
27. Kekatpure VD, Dannenberg AJ, Subbaramaiah K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem 2009;284:7436-45.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265- 75.
29. Ali JA, Jackson AP, Howells AJ, Maxwell A. The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs. Biochemistry 1993;32:2717-24.
30. Alexandrov K, Rojas M, Geneste O, Castegnaro M, Camus AM, Petruzzelli S, et al. An improved fl uorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers' lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res 1992;52:6248-53.
31. Alexandrov K, Rojas M, Kadlubar FF, Lang NP, Bartsch H. Evidence of anti-benzo[a]pyrene diolepoxide-DNA adduct formation in human colon mucosa. Carcinogenesis 1996;17:2081-3.
32. Shugart L, Holland JM, Rahn RO. Dosimetry of PAH skin carcinogenesis: covalent binding of benzo[a]pyrene to mouse epidermal DNA. Carcinogenesis 1983;4:195-8. (Pubitemid 13127703)
33. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 2002;1:47-55.
34. Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, Singh S, et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell 2002;10:1307-18. (Pubitemid 36050873)
35. Kim JH, Stansbury KH, Walker NJ, Trush MA, Strickland PT, Sutter TR. Metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis 1998;19:1847-53. (Pubitemid 28474651)
36. Miller KP, Ramos KS. Impact of cellular metabolism on the biological effects of benzo[a]pyrene and related hydrocarbons. Drug Metab Rev 2001;33:1-35. (Pubitemid 32193758)
37. Mohebati A, Guttenplan JB, Kochhar A, Zhao ZL, Kosinska W, Subbaramaiah K, et al. Carnosol, a constituent of Zyflamend, inhibits aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and mutagenesis. Cancer Prev Res 2012;5:593-602.
38. Vahakangas K, Raunio H, Pasanen M, Sivonen P, Park SS, Gelboin HV, et al. Comparison of the formation of benzo[a]pyrene diolepoxide-DNA adducts in vitro by rat and human microsomes: evidence for the involvement of P-450IA1 and P-450IA2. J Biochem Toxicol 1989;4:79-86.
39. Denis M, Cuthill S, Wikstrom AC, Poellinger L, Gustafsson JA. Association of the dioxin receptor with the Mr 90,000 heat shock protein: a structural kinship with the glucocorticoid receptor. Biochem Biophys Res Commun 1988;155:801- 7.
40. Perdew GH. Association of the Ah receptor with the 90-kDa heat shock protein. J Biol Chem 1988;263:13802-5.
41. Hughes D, Guttenplan JB, Marcus CB, Subbaramaiah K, Dannenberg AJ. Heat shock protein 90 inhibitors suppress aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and DNA adduct formation. Cancer Prev Res 2008;1:485-93.
42. Nair S, Kekatpure VD, Judson BL, Rifkind AB, Granstein RD, Boyle JO, et al. UVR exposure sensitizes keratinocytes to DNA adduct formation. Cancer Prev Res 2009;2:895-902.
43. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011;478:197-203.
44. Menendez D, Shatz M, Resnick MA. Interactions between the tumor suppressor p53 and immune responses. Curr Opin Oncol 2013;25:85-92.
45. Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006;98:441-50.
46. Mai PL, Malkin D, Garber JE, Schiffman JD, Weitzel JN, Strong LC, et al. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet 2012;205:479-87.
47. Hwang SJ, Cheng LS, Lozano G, Amos CI, Gu X, Strong LC. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 2003;113:238-43. (Pubitemid 36992282)
48. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
49. Uno S, Dalton TP, Derkenne S, Curran CP, Miller ML, Shertzer HG, et al. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochromeP450 is more important than metabolic activation. Mol Pharmacol 2004;65:1225-37.
50. DiGiovanni J, Berry DL, Gleason GL, Kishore GS, Slaga TJ. Time-dependent inhibition by 2,3,7,8-tetrachlorodibenzo-p-dioxin of skin tumorigenesis with polycyclic hydrocarbons. Cancer Res 1980;40:1580-7. (Pubitemid 10102004)